Recent studies argue that patients with MGMT-unmethylated GBM tumors show limited benefit of TMZ but have not considered circadian time as an important variable for both measuring Mgmt methylation and assessing TMZ efficacy [11]. This evidence concerns the gene MGMT and glioblastoma.